Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Cancer
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Vidac secures funding to advance skin cancer trials of novel ointment
AngioDynamics launches long-term study of NanoKnife for prostate cancer
Zymeworks doses first subject in Phase I trial of ZW171 for various forms of cancer
FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study
Ossium treats first leukaemia patient in cryopreserved bone marrow trial
FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor
